Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.
On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S. until the end of 2022.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Aktie
296,30 €
-0,62 %
Mit 28 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ist Amgen Inc. einer der Lieblinge unserere Community.
Das Kursziel von 304 € für Amgen Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 296.3 € hin.
